New level of data analysis unlocked as Insilico Medicine launch 'natural language' ChatPandaGPT

Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-powered drug discovery company, has integrated ChatGPT into its PandaOmics platform. 

PandaOmics is an AI-driven target discovery platform developed by Insilico Medicine which applies deep learning modules to identify therapeutic targets associated with a given disease. The new feature “ChatPandaGPT”, allows researchers to have a natural language conversation with the platform, enabling the navigation and analysis of large data sets for more efficient discovery of potential therapeutic targets and biomarkers. 

"Insilico Medicine is excited to integrate this cutting-edge chat functionality into our PandaOmics platform," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "By enabling researchers to have natural language conversations with the platform, we’re making it easier to navigate complex data and identify potential therapeutic targets and biomarkers."

Insilico Medicine is the first biotech company to implement a chat functionality using large language molecules into its AI drug discovery platform.